Tiotropium (Spiriva) Rehabilitation Study
Public ClinicalTrials.gov record NCT00274521. Field values are reproduced from the official study page; the official ClinicalTrials.gov record remains the source of truth for eligibility, enrollment, and contact information.
Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.
Official title
A Randomized, Double-blind, Placebo Controlled 25-week Trial to Compare the Effect of Tiotropium Inhalation Capsuled (18 Mcg) Once Daily on Exercise Tolerance in Patients With Chronic Obstructive Pulmonary Disease (COPD) Participating in 8 Weeks of Pulmonary Rehabilitation.
Study identification
- NCT ID
- NCT00274521
- Recruitment status
- Completed
- Study type
- Interventional
- Phase
- Phase 3
- Lead sponsor
- Boehringer Ingelheim
- Industry
- Enrollment
- 108 participants
Conditions and interventions
Conditions
Interventions
- Tiotropium Drug
Drug
Eligibility (public fields only)
- Age range
- 40 Years and older
- Sex
- All
- Healthy volunteers
- Healthy volunteers not accepted
This page does not interpret eligibility. Detailed inclusion and exclusion criteria are on the official ClinicalTrials.gov record.
Study timeline
- Start date
- Apr 30, 2001
- Primary completion
- Jan 31, 2003
- Completion
- Not listed
- Last update posted
- Oct 31, 2013
Started 2001
United States locations
- U.S. sites
- 19
- U.S. states
- 12
- U.S. cities
- 19
| Facility | City | State | ZIP | Site status |
|---|---|---|---|---|
| University of Alabama at Birmingham | Birmingham | Alabama | — | — |
| Boehringer Ingelheim Investigational Site | Phoenix | Arizona | — | — |
| Attention: John E. Hodgkin, M.D. | Deer Park | California | — | — |
| Boehringer Ingelheim Investigational Site | Long Beach | California | — | — |
| UCLA School of Medicine | Los Angeles | California | — | — |
| Boehringer Ingelheim Investigational Site | San Diego | California | — | — |
| Harbor-UCLA Research and Education Institute | Torrance | California | — | — |
| Boehringer Ingelheim Investigational Site | Fort Collins | Colorado | — | — |
| Boehringer Ingelheim Investigational Site | Wheat Ridge | Colorado | — | — |
| Boehringer Ingelheim Investigational Site | Danbury | Connecticut | — | — |
| St. Francis Hospital and Medical Center | Hartford | Connecticut | — | — |
| Norwalk Hospital | Norwalk | Connecticut | — | — |
| Boehringer Ingelheim Investigational Site | Elk Grove Village | Illinois | — | — |
| UMass Memorial Medical Center | North Worcester | Massachusetts | — | — |
| Henry Ford Hospital | Detroit | Michigan | — | — |
| University of Nebraska Medical Center | Omaha | Nebraska | — | — |
| Duke University Medical Center | Durhan | North Carolina | — | — |
| Temple University Hospital | Philadelphia | Pennsylvania | — | — |
| Boehringer Ingelheim Investigational Site | Everett | Washington | — | — |
Site contact phone numbers, emails, and investigator names are intentionally not displayed here. Open the official ClinicalTrials.gov record for site contact information.
About this trial record page
- What this page shows
- Public field values for ClinicalTrials.gov record NCT00274521, including study identification, conditions, interventions, eligibility (age, sex, healthy volunteer), timeline, and U.S. site list.
- What this page does not do
- No medical advice, eligibility judgments, treatment recommendations, study quality scoring, or AI-generated medical summaries. No site contact phone numbers, emails, or investigator names.
- Where the data comes from
- Sourced from the official ClinicalTrials.gov public API. The official record is the source of truth.
- Last refresh
- Last update posted Oct 31, 2013 · Synced Jul 24, 2026
Related: full search, browse by condition, browse by drug or therapy, browse by sponsor, browse by U.S. city.
Open the official record
The complete protocol, eligibility criteria, and contact information for NCT00274521 live on ClinicalTrials.gov.